11月25日，西点药业盘中上涨2.05%，截至09:44，报30.90元/股，成交544.71万元，换手率0.30%，总市 值23.64亿元。 西点药业今年以来股价涨18.89%，近5个交易日跌4.10%，近20日跌1.65%，近60日跌5.65%。 资料显示，吉林省西点药业科技发展股份有限公司位于吉林省磐石经济开发区西点大街777号，成立日 期1990年3月21日，上市日期2022年2月23日，公司主营业务涉及化学药品原料药及制剂的研发、生产、 销售。主营业务收入构成为：利培酮口崩片54.15%，复方硫酸亚铁叶酸片45.13%，其他(补充)0.72%。 西点药业所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：微盘股、小盘、肝炎治 疗、原料药、中药等。 截至9月30日，西点药业股东户数7863.00，较上期减少2.91%；人均流通股7426股，较上期增加2.97%。 2025年1月-9月，西点药业实现营业收入1.89亿元，同比减少1.89%；归母净利润3314.64万元，同比减少 2.70%。 分红方面，西点药业A股上市后累计派现6333.72万元。近三年，累计派现5283.26万元。 责任编 ...

11月24日，美康生物盘中上涨2.07%，截至13:51，报10.37元/股，成交2881.68万元，换手率0.96%，总 市值39.85亿元。 资金流向方面，主力资金净流出291.42万元，大单买入185.30万元，占比6.43%，卖出476.72万元，占比 16.54%。 截至9月30日，美康生物股东户数2.39万，较上期减少6.95%；人均流通股12234股，较上期增加7.47%。 2025年1月-9月，美康生物实现营业收入11.36亿元，同比减少19.27%；归母净利润6053.38万元，同比减 少73.02%。 分红方面，美康生物A股上市后累计派现3.88亿元。近三年，累计派现1.43亿元。 机构持仓方面，截止2025年9月30日，美康生物十大流通股东中，医疗器械ETF（159883）位居第五大 流通股东，持股142.34万股，为新进股东。 责任编辑：小浪快报 美康生物今年以来股价涨0.53%，近5个交易日跌4.95%，近20日跌1.14%，近60日跌9.98%。 资料显示，美康生物科技股份有限公司位于浙江省宁波市鄞州区金达南路1228号，成立日期2003年7月 22日，上市日期2015年4月22日 ...

资料显示，华东医药股份有限公司位于浙江省杭州市拱墅区莫干山路858号华东医药新写字楼，成立日 期1993年3月31日，上市日期2000年1月27日，公司主营业务涉及生产销售百令胶囊、新赛斯平(口服 液、软胶囊)、泮立苏、卡博平等产品、医药批发。主营业务收入构成为：商业64.45%，制造业 39.69%，其中:工业33.76%，其中:医美业务5.13%，其中:国内医美3.35%，其中:国际医美业务2.42%。 华东医药所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：维生素、中药、肝炎治 疗、医药电商、医疗美容等。 11月24日，华东医药盘中上涨2.03%，截至10:11，报41.18元/股，成交9616.13万元，换手率0.13%，总 市值722.31亿元。 截至9月30日，华东医药股东户数6.88万，较上期减少1.50%；人均流通股25466股，较上期增加1.53%。 2025年1月-9月，华东医药实现营业收入326.64亿元，同比增长3.77%；归母净利润27.48亿元，同比增长 7.24%。 资金流向方面，主力资金净流入95.64万元，特大单买入124.23万元，占比1.29%，卖出142 ...

金城医药所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：合成生物、宠物经济、 石墨烯、肝炎治疗、医疗美容等。 11月24日，金城医药（维权）盘中上涨2.05%，截至09:36，报16.39元/股，成交1657.71万元，换手率 0.27%，总市值62.92亿元。 资金流向方面，主力资金净流出416.42万元，特大单买入0.00元，占比0.00%，卖出100.86万元，占比 6.08%；大单买入256.26万元，占比15.46%，卖出571.82万元，占比34.49%。 金城医药今年以来股价涨41.23%，近5个交易日跌6.88%，近20日跌5.21%，近60日跌11.84%。 今年以来金城医药已经3次登上龙虎榜，最近一次登上龙虎榜为3月25日，当日龙虎榜净买入1.22亿元； 买入总计3.09亿元 ，占总成交额比19.80%；卖出总计1.87亿元 ，占总成交额比11.96%。 资料显示，山东金城医药集团股份有限公司位于山东省淄博市淄川经济开发区双山路1号，成立日期 2004年1月12日，上市日期2011年6月22日，公司主营业务涉及医药中间体、原料药以及终端制剂的研 发、生产和销售。主营业务收入 ...

Core Viewpoint - The stock of Kingdawei has experienced a decline recently, with a notable drop in trading volume and fluctuations in shareholder numbers, despite a year-to-date increase in stock price and significant growth in revenue and net profit [1][2]. Financial Performance - For the period from January to September 2025, Kingdawei achieved a revenue of 2.604 billion yuan, representing a year-on-year growth of 11.16% [2]. - The net profit attributable to shareholders for the same period was 361 million yuan, showing a substantial increase of 63.47% compared to the previous year [2]. Stock Market Activity - As of November 21, Kingdawei's stock price was 18.96 yuan per share, with a market capitalization of 11.564 billion yuan [1]. - The stock has increased by 28.98% year-to-date, but has seen a decline of 9.11% over the last five trading days [1]. Shareholder Information - As of September 30, the number of shareholders for Kingdawei was 36,300, a decrease of 10.95% from the previous period [2]. - The average number of circulating shares per shareholder increased by 12.29% to 16,817 shares [2]. Dividend Distribution - Kingdawei has distributed a total of 2.761 billion yuan in dividends since its A-share listing, with 488 million yuan distributed over the last three years [3]. Institutional Holdings - As of September 30, 2025, Hong Kong Central Clearing Limited was the fourth largest circulating shareholder, holding 7.7408 million shares, an increase of 803,600 shares from the previous period [3]. - The Southern CSI 1000 ETF and Huaxia CSI 1000 ETF were among the top ten circulating shareholders, with slight changes in their holdings [3].

Core Viewpoint - Huadong Medicine's stock price has experienced fluctuations, with a year-to-date increase of 19.81% but a recent decline of 6.51% over the past five trading days [1] Financial Performance - For the period from January to September 2025, Huadong Medicine achieved a revenue of 32.664 billion yuan, representing a year-on-year growth of 3.77%, and a net profit attributable to shareholders of 2.748 billion yuan, up 7.24% year-on-year [2] Shareholder Information - As of September 30, 2025, the number of Huadong Medicine's shareholders decreased by 1.50% to 68,800, while the average circulating shares per person increased by 1.53% to 25,466 shares [2] - The company has distributed a total of 8.873 billion yuan in dividends since its A-share listing, with 3.771 billion yuan distributed over the past three years [3] Stockholder Composition - The top circulating shareholder, Hong Kong Central Clearing Limited, increased its holdings by 12.1653 million shares to 52.0036 million shares [3] - China Securities Finance Corporation maintained its position as the fourth-largest shareholder with 22.1868 million shares, while other notable shareholders saw reductions in their holdings [3] Business Overview - Huadong Medicine, established on March 31, 1993, and listed on January 27, 2000, is primarily engaged in the production and sale of various pharmaceutical products, with a revenue composition of 64.45% from commercial activities and 39.69% from manufacturing [1] - The company operates in several sectors, including vitamins, traditional Chinese medicine, hepatitis treatment, pharmaceutical e-commerce, and medical aesthetics [1]

迪瑞医疗今年以来股价跌16.23%，近5个交易日跌4.87%，近20日跌2.95%，近60日跌10.79%。 资料显示，迪瑞医疗科技股份有限公司位于吉林省长春市高新技术产业开发区宜居路3333号，成立日期 1994年12月26日，上市日期2014年9月10日，公司主营业务涉及医疗检验仪器及配套试纸试剂的研发、 生产与销售。主营业务收入构成为：试剂57.13%，仪器42.24%，其他0.63%。 11月21日，迪瑞医疗盘中下跌2.04%，截至10:09，报13.47元/股，成交1507.91万元，换手率0.41%，总 市值36.73亿元。 资金流向方面，主力资金净流入40.73万元，大单买入115.14万元，占比7.64%，卖出74.41万元，占比 4.93%。 截至9月30日，迪瑞医疗股东户数1.68万，较上期减少6.48%；人均流通股16159股，较上期增加6.92%。 2025年1月-9月，迪瑞医疗实现营业收入4.69亿元，同比减少60.12%；归母净利润-8725.40万元，同比减 少145.31%。 分红方面，迪瑞医疗A股上市后累计派现9.23亿元。近三年，累计派现3.40亿元。 机构持仓方面，截止2 ...

11月21日，海辰药业盘中下跌2.12%，截至09:35，报58.07元/股，成交5327.78万元，换手率1.11%，总 市值69.68亿元。 资金流向方面，主力资金净流出92.90万元，特大单买入139.00万元，占比2.61%，卖出0.00元，占比 0.00%；大单买入917.99万元，占比17.23%，卖出1149.89万元，占比21.58%。 海辰药业今年以来股价涨189.48%，近5个交易日跌19.24%，近20日涨9.13%，近60日涨9.73%。 海辰药业所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：电解液、原料药、锂电 池、固态电池、肝炎治疗等。 截至11月10日，海辰药业股东户数2.21万，较上期减少2.84%；人均流通股3709股，较上期增加2.93%。 2025年1月-9月，海辰药业实现营业收入4.72亿元，同比增长30.80%；归母净利润3267.85万元，同比增 长16.22%。 分红方面，海辰药业A股上市后累计派现1.61亿元。近三年，累计派现1800.00万元。 机构持仓方面，截止2025年9月30日，海辰药业十大流通股东中，中欧悦享生活混合A（010336） ...

Core Viewpoint - The stock of Kingdawei has experienced fluctuations, with a recent decline of 2.00% and a year-to-date increase of 33.27%, indicating volatility in its market performance [1]. Financial Performance - As of September 30, Kingdawei reported a revenue of 2.604 billion yuan, representing a year-on-year growth of 11.16% [2]. - The net profit attributable to shareholders for the same period was 361 million yuan, showing a significant increase of 63.47% year-on-year [2]. Shareholder Information - The number of shareholders as of September 30 is 36,300, a decrease of 10.95% from the previous period [2]. - The average circulating shares per person increased by 12.29% to 16,817 shares [2]. Dividend Distribution - Kingdawei has distributed a total of 2.761 billion yuan in dividends since its A-share listing, with 488 million yuan distributed over the past three years [3]. Institutional Holdings - As of September 30, the fourth largest circulating shareholder is Hong Kong Central Clearing Limited, holding 7.7408 million shares, an increase of 803,600 shares from the previous period [3]. - The seventh largest circulating shareholder is Southern CSI 1000 ETF, holding 2.7924 million shares, which decreased by 20,500 shares [3]. - The tenth largest circulating shareholder is Huaxia CSI 1000 ETF, holding 1.6575 million shares, with a reduction of 4,900 shares [3].

Core Viewpoint - Fujian Pharmaceutical Co., Ltd. has experienced significant stock price increases this year, with a 120.14% rise year-to-date and a 25.93% increase in the last five trading days, indicating strong market interest and potential investment opportunities [1][2]. Financial Performance - For the period from January to September 2025, Fujian Pharmaceutical reported a revenue of 769 million yuan, a year-on-year decrease of 21.24%, and a net profit attributable to shareholders of -62.75 million yuan, a slight decrease of 1.09% [2]. - The company has cumulatively distributed 359 million yuan in dividends since its A-share listing, with no dividends paid in the last three years [3]. Stock Market Activity - As of November 19, the stock price reached 18.36 yuan per share, with a trading volume of 502 million yuan and a turnover rate of 6.20%, resulting in a total market capitalization of 9.89 billion yuan [1]. - The stock has appeared on the "Dragon and Tiger List" three times this year, with the most recent appearance on November 17, where it recorded a net buy of -40.63 million yuan [1]. Shareholder Information - As of September 30, 2025, the number of shareholders decreased by 7.87% to 20,700, while the average circulating shares per person increased by 5.59% to 21,347 shares [2].